Activation by reductive cleavage of potentially cytotoxic azo compounds by human hepatocellular carcinoma.
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001391:Azo Compounds / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000201:enzymology / Q000378:metabolism*; D005260:Female; D000882:Haplorhini; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000201:enzymology; D008113:Liver Neoplasms / Q000139:chemically induced / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000032:analysis; D010084:Oxidation-Reduction; D010215:Papio; D051381:Rats; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001391:Azo Compounds; D009363:Neoplasm Proteins